Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

Authors

Shigeo Muro (ORCID: https://orcid.org/0000-0001-7452-9191)
Munehiro Seki (ORCID: https://orcid.org/0000-0002-7899-9120)
Jonathan Marshall (ORCID: https://orcid.org/0000-0001-5296-6075)
Patrick Darken (ORCID: https://orcid.org/0000-0002-5608-2717)
John Robert Hurst (ORCID: https://orcid.org/0000-0002-7246-6040)
David Petullo
Elizabeth Duncan (ORCID: https://orcid.org/0000-0002-9369-1351)
Mehul S. Patel (ORCID: https://orcid.org/0000-0003-0435-858X)
Ayman Megally
Karin Bowen

Institutions

AstraZeneca (United Kingdom) (GB)
AstraZeneca (Japan) (JP)
AstraZeneca (United States) (US)
University College London (GB)
Nara Medical University (JP)

Publication Details

Journal: International Journal of COPD
Published: 2024-12-01
DOI: https://doi.org/10.2147/copd.s478349
Citations: 2
Primary Topic: Asthma and respiratory diseases
Type: article
Field-Weighted Citation Impact: 0.65

Funders

AstraZeneca

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

Shigeo Muro, Munehiro Seki, Jonathan Marshall, Patrick Darken et al.

Dec 1, 2024

2 citations

International Journal of COPD

Asthma and respiratory diseases

0.65

article

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

Shigeo Muro, Munehiro Seki, Jonathan Marshall, Patrick Darken, John Robert Hurst, David Petullo, Elizabeth Duncan, Mehul S. Patel, Ayman Megally, Karin Bowen

December 1, 2024article en

2 citations

Abstract

No abstract available for this paper.

International Journal of COPDVol. Volume 19

AstraZeneca (United Kingdom) (GB), AstraZeneca (Japan) (JP), AstraZeneca (United States) (US), University College London (GB), Nara Medical University (JP)

AstraZeneca

Openalex Percentile: Top 27%

Asthma and respiratory diseases

0.65

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.